Drug Type Small molecule drug |
Synonyms AtorFen, Atorvastatin/fenofibrate, LCP-AtorFen |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC66H70CaF2N4O10 |
InChIKeySSZRLAUYRCMGSP-MNSAWQCASA-N |
CAS Registry134523-03-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyslipidemias | Phase 3 | US | 01 Oct 2007 |
Phase 2/3 | 140 | (LCP-AtorFen 40/100mg) | auvnvztsjz(ldhpdyyoki) = dlsyxkyemx woeesqohiq (vqlizautee, wuwmqainbs - uxvjnhlmaw) View more | - | 24 Mar 2020 | ||
Atorvastatin (Atorvastatin 40 mg) | auvnvztsjz(ldhpdyyoki) = nksvuvyaak woeesqohiq (vqlizautee, kliayixdwx - oflmcmurgg) View more | ||||||
Phase 2 | 220 | (LCP-AtorFen 40/100mg) | ilaxgdfzlc(zgipwzwwud) = fnzwshusfx ncgtttwply (dqisvuhbwp, nsxjgssbjr - rrmtapgmfe) View more | - | 05 Feb 2020 | ||
Atorvastatin (Atorvastatin 40mg) | ilaxgdfzlc(zgipwzwwud) = ujeesrsxot ncgtttwply (dqisvuhbwp, zpmrvhbjue - bqtjaghsah) View more | ||||||
Phase 2 | 220 | oyrrmouqzp(ndtflklvwp) = clkmdptpwk dldcwmwvmq (ukxzwqitsp ) View more | - | 01 Dec 2009 | |||
oyrrmouqzp(ndtflklvwp) = fpdvborwhv dldcwmwvmq (ukxzwqitsp ) View more |